coronaviru
diseas
emerg
global
health
crisi
confirm
case
date
pandem
continu
expand
spur
research
discov
vaccin
therapi
novel
coronaviru
respons
diseas
initi
entri
human
cell
bind
angiotensinconvert
enzym
via
receptor
bind
domain
rbd
spike
protein
disrupt
bind
design
drug
potenti
inhibit
viru
enter
human
cell
present
new
modal
therapeut
intervent
peptidebas
binder
attract
solut
inhibit
interact
adequ
cover
extend
protein
contact
interfac
use
molecular
dynam
simul
base
recent
solv
cocryst
structur
observ
peptidas
domain
pd
helix
import
bind
use
autom
fastflow
peptid
synthesi
chemic
synthes
peptid
fragment
pd
helix
compos
entir
proteinogen
amino
acid
chemic
synthesi
human
deriv
sequenc
complet
hour
work
isol
milligram
pure
materi
obtain
biolay
interferometri
reveal
peptid
specif
associ
low
nanomolar
affin
peptid
binder
provid
new
avenu
treatment
diagnost
modal
block
spike
protein
interact
thu
preclud
viru
entri
human
cell
novel
coronaviru
wuhan
china
caus
confirm
case
death
global
accord
situat
report
mar
http
number
continu
grow
similar
sarscov
outbreak
caus
sever
respiratori
problem
cough
fever
difficulti
breath
andor
shortag
breath
common
symptom
age
patient
preexist
medic
condit
risk
mortal
rate
even
higher
region
moreov
humantohuman
transmiss
occur
rapidli
close
contact
slow
pandem
treat
infect
patient
rapid
develop
specif
antivir
drug
highest
urgenc
closelyrel
sarscov
coronaviru
invad
host
cell
bind
convert
enzym
receptor
human
cell
surfac
viral
spike
protein
recent
establish
use
receptor
host
cell
entri
recent
crystallograph
studi
receptor
bind
domain
rbd
length
human
receptor
reveal
key
amino
acid
residu
contact
interfac
two
protein
provid
valuabl
structur
inform
leverag
develop
disruptor
specif
proteinprotein
interact
ppi
smallmolecul
inhibitor
often
less
effect
disrupt
extend
protein
bind
interfac
peptid
hand
offer
synthet
access
solut
disrupt
ppi
bind
interfac
region
contain
multipl
contact
hot
spot
hypothes
disrupt
viral
interact
peptidebas
binder
prevent
viru
entri
human
cell
offer
novel
opportun
therapeut
intervent
toward
aim
launch
campaign
rapidli
discov
peptid
binder
analyz
cocryst
structur
found
interfac
span
larg
elong
surfac
area
common
ppi
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
leverag
molecular
dynam
simul
autom
fastflow
peptid
synthesi
prepar
peptid
binder
sequenc
deriv
helix
use
biolay
interferometri
determin
bind
low
nanomolar
affin
dissoci
constant
k
nm
firstinclass
peptid
binder
potenti
inhibit
entri
viru
human
cell
addit
human
proteinderiv
sequenc
fulli
proteinogen
expect
immunogen
taken
togeth
comput
simul
coupl
autom
flow
peptid
synthesi
technolog
enabl
acceler
discoveri
loop
design
experiment
valid
rapidli
deliv
promis
preclin
drug
lead
use
amber
forc
field
helic
peptid
sequenc
spikebind
peptid
deriv
helix
peptidas
domain
complex
simul
explicit
water
condit
analyz
simul
trajectori
ns
found
remain
spike
rbd
protein
surfac
stabl
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
autom
fastflow
peptid
synthesi
yield
pure
compound
two
biotinyl
peptid
deriv
helix
prepar
autom
fastflow
peptid
synthesi
total
synthesi
time
h
total
coupl
cleavag
resin
global
deprotect
subsequ
solidphas
extract
puriti
crude
peptid
estim
biotinyl
base
lcm
tic
chromatogram
supplement
fig
assess
puriti
accept
direct
downstream
biolog
character
biolay
interferometri
employ
measur
affin
synthes
peptid
eg
glycosyl
human
protein
menin
neg
control
biotinyl
peptid
immobil
onto
streptavidin
sa
biosensor
fit
associ
dissoci
curv
serial
dilut
protein
dissoci
constant
kd
rbd
determin
nm
averag
k
k
fig
howev
truncat
associ
spike
rbd
protein
fig
observ
bind
neg
control
human
protein
menin
fig
togeth
data
indic
specif
bind
low
nanomolar
affin
recent
publish
cryoem
cocryst
structur
rbd
human
identifi
ppi
key
step
entri
human
cell
block
bind
interfac
repres
highli
promis
therapeut
strategi
could
potenti
hinder
enter
cell
replic
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
drug
ppi
longstand
challeng
tradit
drug
discoveri
peptidebas
approach
might
help
solv
problem
small
molecul
compound
unlik
bind
larg
protein
surfac
distinct
bind
pocket
peptid
hand
display
larger
surfac
area
chemic
function
mimic
disrupt
nativ
ppi
case
clinic
approv
hiv
peptid
drug
fuzeon
identif
suitabl
start
point
drug
discoveri
campaign
time
smaller
nm
start
coordin
fig
result
indic
potenti
identifi
peptid
deriv
human
helix
peptid
sequenc
synthes
autom
flow
peptid
synthesi
residu
select
helix
sequenc
ieeqaktfldkfnheaedlfyq
show
low
fluctuat
along
md
simul
trajectori
sever
import
interact
spike
protein
observ
consist
multipl
line
publish
data
decid
use
peptid
experiment
start
point
develop
spike
protein
binder
rapid
autom
flow
peptid
synthes
enabl
synthesi
ten
milligram
peptid
within
minut
crude
puriti
determin
therefor
suffici
bind
valid
biolay
interferometri
bli
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
interact
rbd
spike
protein
valid
biolay
interferometri
k
deriv
protein
associ
dissoci
kinet
found
nm
averag
fit
valu
differ
protein
concentr
fig
bind
affin
compar
full
length
bind
nm
excess
therefor
could
potenti
cover
spike
protein
surfac
outcompet
bind
optim
sequenc
length
amino
acid
composit
progress
order
produc
binder
higher
ppi
inhibitori
activ
fulli
human
endogen
peptid
therefor
like
well
toler
human
immun
system
amino
acid
sequenc
entir
deriv
human
recogn
endogen
human
immun
system
featur
could
highli
benefici
later
stage
preclin
develop
challeng
associ
peptid
drug
proteolyt
degrad
rapid
renal
elimin
address
near
futur
chemic
modif
sequenc
conclus
peptid
sequenc
deriv
human
found
bind
spike
protein
rbd
low
nanomolar
affin
believ
disrupt
bind
interfac
highaffin
peptid
repres
promis
strategi
prevent
viru
entri
human
cell
pave
way
new
treatment
diagnost
modal
upon
request
make
avail
peptid
binder
upcom
optim
variant
research
facil
test
develop
potenti
treatment
rapid
discoveri
synthesi
test
potenti
drug
lead
help
global
scientif
healthcar
commun
effici
address
ongo
crisi
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
cocryst
structur
pdb
chosen
initi
structur
explicitli
solvat
box
perform
ns
molecular
dynam
md
simul
use
namd
mit
supercomput
cluster
gpu
node
amber
forc
field
use
model
protein
peptid
md
simul
system
equilibr
k
ns
period
boundari
condit
use
longrang
electrostat
interact
calcul
particl
mesh
ewald
method
nonbond
cutoff
set
shake
algorithm
use
constrain
bond
involv
hydrogen
atom
time
step
fs
trajectori
record
everi
ps
simul
product
run
trajectori
file
load
vmd
softwar
analysi
peptid
synthesi
peptidyl
resin
rins
dichloromethan
briefli
dri
vacuum
chamber
overnight
next
day
approxim
ml
cleavag
solut
tfa
tip
edt
water
ad
syring
contain
resin
syring
kept
room
temperatur
h
inject
cleavag
solut
ml
conic
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
